La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Dynavax Technologies Gestione
Gestione criteri di controllo 4/4
Dynavax Technologies' Il CEO è Ryan Spencer, nominato in Dec2019, e ha un mandato di 4.67 anni. la retribuzione annua totale è $ 5.81M, composta da 13.1% di stipendio e 86.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.18% delle azioni della società, per un valore di $ 2.63M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.6 anni e 6.2 anni.
Informazioni chiave
Ryan Spencer
Amministratore delegato
US$5.8m
Compenso totale
| Percentuale dello stipendio del CEO | 13.1% |
| Mandato del CEO | 4.7yrs |
| Proprietà del CEO | 0.2% |
| Durata media del management | 3.6yrs |
| Durata media del Consiglio di amministrazione | 6.2yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings
Aug 14
Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
Jul 12Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S
May 22Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain
May 10Dynavax: Holding Firm Despite Its Missing Cash Cow
Mar 23Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Mar 06Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry
Jan 31These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely
Aug 02Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet
Jun 02We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease
May 03Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly
Jan 16Clover, Dynavax COVID-19 vaccine gets EU GMP certificate
Sep 20Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Sep 12The Alphavaxers: Dynavax And Novavax, 2 Quarters On
Aug 22Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats
Aug 04Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?
Jun 03Dynavax: Evolving Endemic Situation Adds To Its Risk
May 23Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest
May 12Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt
May 10Dynavax Technologies: Full Speed Ahead
Mar 01Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly
Jan 28Dynavax: A Coronavirus Growth Story
Jan 17Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 18The Momentum Investor: Spotlight On Dynavax Technologies
Oct 25Dynavax And TLR Biology: Long-Delayed But Outstanding Success
Oct 16These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well
Oct 02Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$17m |
| Mar 31 2024 | n/a | n/a | US$9m |
| Dec 31 2023 | US$6m | US$760k | -US$6m |
| Sep 30 2023 | n/a | n/a | US$61m |
| Jun 30 2023 | n/a | n/a | US$111m |
| Mar 31 2023 | n/a | n/a | US$236m |
| Dec 31 2022 | US$6m | US$695k | US$293m |
| Sep 30 2022 | n/a | n/a | US$320m |
| Jun 30 2022 | n/a | n/a | US$228m |
| Mar 31 2022 | n/a | n/a | US$104m |
| Dec 31 2021 | US$5m | US$600k | US$72m |
| Sep 30 2021 | n/a | n/a | -US$39m |
| Jun 30 2021 | n/a | n/a | -US$6m |
| Mar 31 2021 | n/a | n/a | -US$62m |
| Dec 31 2020 | US$2m | US$515k | -US$75m |
| Sep 30 2020 | n/a | n/a | -US$97m |
| Jun 30 2020 | n/a | n/a | -US$138m |
| Mar 31 2020 | n/a | n/a | -US$129m |
| Dec 31 2019 | US$3m | US$391k | -US$156m |
Compensazione vs Mercato: La retribuzione totale di Ryan ($USD 5.81M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 5.62M ).
Compensazione vs guadagni: La retribuzione di Ryan è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Ryan Spencer (46 yo)
4.7yrs
Mandato
US$5,810,736
Compensazione
Mr. Ryan Spencer serves as Independent Director at Cidara Therapeutics, Inc. from April 24, 2024. He serves as Interim Chief Financial Officer of Dynavax Technologies Corporation since March 29, 2024. He s...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, Interim CFO & Director | 4.7yrs | US$5.81m | 0.18% $ 2.6m | |
| President & COO | 11.4yrs | US$2.99m | 0.024% $ 365.7k | |
| Chief Medical Officer and Senior VP of Clinical Development | 11.1yrs | US$1.88m | 0.049% $ 735.8k | |
| Senior VP & CFO (Leave of Absence) | less than a year | US$2.07m | 0.0059% $ 88.1k | |
| Chief Accounting Officer & Controller | 4.3yrs | Nessun dato | Nessun dato | |
| Senior VP & Chief Human Resources Officer | 5.6yrs | Nessun dato | Nessun dato | |
| VP of Investor Relations & Corporate Communications | 1.6yrs | Nessun dato | Nessun dato | |
| Senior VP & General Counsel | 3.2yrs | Nessun dato | Nessun dato | |
| Senior VP & Chief Commercial Officer | no data | Nessun dato | Nessun dato | |
| Senior Vice President of Vaccine Research | 3.5yrs | Nessun dato | Nessun dato | |
| VP, Site Head & MD for Dynavax GmbH | 3.6yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Technical Operations | 3.6yrs | Nessun dato | Nessun dato |
3.6yrs
Durata media
59.5yo
Età media
Gestione esperta: Il team dirigenziale di DVAX è considerato esperto (durata media dell'incarico 3.6 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, Interim CFO & Director | 4.7yrs | US$5.81m | 0.18% $ 2.6m | |
| Independent Director | 18yrs | US$298.73k | 0.021% $ 317.5k | |
| Independent Director | 14.1yrs | US$290.73k | 0.0011% $ 17.1k | |
| Independent Director | 14.8yrs | US$278.73k | 0.016% $ 238.6k | |
| Member of Scientific Advisory Board | 1.6yrs | US$1.83m | Nessun dato | |
| Member of Scientific Advisory Board | 6.2yrs | Nessun dato | Nessun dato | |
| Independent Director | 4.1yrs | US$293.73k | 0% $ 0 | |
| Member of Scientific Advisory Board | 6.2yrs | US$20.00k | Nessun dato | |
| Independent Chairman of the Board | 2.8yrs | US$323.73k | 0% $ 0 | |
| Member of Scientific Advisory Board | 6.2yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 6.2yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 6.2yrs | Nessun dato | Nessun dato |
6.2yrs
Durata media
73.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di DVAX sono considerati esperti (durata media dell'incarico 6.2 anni).